A promising drug , retatrutide, is generating considerable anticipation within the Oz weight loss community. Developed by Lilly , this dual GIP and GLP-1 receiver appears to offer more impressive results than existing therapies. Initial scientific studies have shown noteworthy decreases in body mass, suggesting the potential for a different method